Inebilizumab

Inebilizumab

Chronic immune diseases

Indication extension

Rheumatism

Inebilizumab monotherapy for preventive treatment of immunoglobulin G4 related disease in adults and elderly at high risk of flare

Uplizna

Amgen

Amgen

Intravenous

Intravenous drip

Intermural (MSZ)

Centralised (EMA)

Normal trajectory

December 2024

October 2025

Clinical trials

Verwachte registratie op basis van gemiddelde doorlooptijd van 10 maanden voor een indicatieuitbreiding.

No estimate possible yet

NCT04540497 (MITIGATE)

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.